



22 June 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

**NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT AND THE ASX CLASS
WAIVER DECISION – TEMPORARY EXTRA PLACEMENT CAPACITY (31 MARCH 2020)**

Further to the ASX announcement made by Medlab Clinical Limited (**Company**) (ASX: MDC) on 15 June 2020, the Company issued 35,984,020 fully paid ordinary shares (**Placement Shares**) at a price of \$0.15 per Placement Share on Friday 19 June 2020.

The Placement Shares were offered to institutional and sophisticated investors pursuant to the placement announcement on 15 June 2020. The Placement Shares were allocated on a pro-rata basis to eligible existing shareholders. Eligible shareholders who bid for up to their pro-rata share of new Placement Shares were allocated their full bid, on a best endeavours basis.¹

As far as the Company is aware, no Placement Shares were issued or agreed to be issued to any person referred to in listing rule 10.11 of the ASX Listing Rules.

The Company provides the following notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**):

1. the company issued the Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of the notice, the company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - b. section 674 of the Corporations Act as it applies to the Company;
3. as at today's date, there is no information that is excluded information which is required to be set out in this notice pursuant to section 708A(7) and 708A(8) of the Act.

For and behalf of the Board.

Alan Dworkin
Company Secretary

¹ For this purpose, an eligible institutional shareholder's 'pro-rata' share will be estimated by reference to the Company's register on 27 May 2020, but without undertaking any reconciliation and ignoring shares that may be issued under the SPP. Accordingly, unlike in a rights issue, this may not truly reflect the participating shareholder's actual pro-rata share. Nothing in this Announcement provides a shareholder a right or entitlement to participate in the Placement and the Company has no obligations to reconcile assumed holdings (e.g. for recent trading or swap positions) when determining a shareholder's 'pro-rata' share. The Company disclaims any duty or liability (including for negligence) in respect of the determination of a shareholder's 'pro-rata' share. Eligible institutional shareholders who bid in excess of their 'pro-rata' share as determined by the Company are expected to be allocated a minimum of their 'pro-rata' share on a best endeavours basis as set out in this footnote, and any excess may be subject to scale back.